This is an extract - CST - ASX release dated 2/10/02
"Cellestis Ltd ("CST") has today signed a contract with Statens Serum
Institut ("SS"), a Danish Government owned company. SSI is a world
leader in tuberculosis research, and a major European producer of
vaccines and other biological products. The contract grants Cellestis
the exclusive rights to use SSI's owned and licensed tuberculosis
specific proteins in CST's QuantiFERON technology. These rights cover
the most significant proteins that are known to be specific to
tuberculosis, and include patent coverage in major markets and
countries until 2015 and beyond."
Add to My Watchlist
What is My Watchlist?
